Immunotherapy Drugs Market 2025: Register Stellar Compound Annual GrowthPosted by Sandeep Salunkhe on April 11th, 2019 The global immunotherapy market is driven by increasing adoption of targeted therapies, increase in life span of patients, and high prevalence of lifestyle diseases. Furthermore, rapid approval of drugs and reduction in recurrence of diseases propel the market growth. However, high cost of immunotherapy treatment and higher attrition rate in the product development cycle impede the market growth. Conversely, immunotherapy as an alternative to chemotherapy and use of immunotherapy as the first line of drug for the treatment of cancer provide growth opportunities in the market players in the near future. The global immunotherapy drugs market is segmented based on therapy area, type of drugs, and region. Based on therapy area, it is divided into cancer, autoimmune & inflammatory diseases, infectious diseases, and others. Cancer is further divided into solid tumor and malignant tumor. Based on type of drugs, it is classified into monoclonal antibodies, adult vaccines, checkpoint inhibitors, interferons alpha & beta, interleukins, and others. Download Sample @ https://www.alliedmarketresearch.com/request-toc-and-sample/3578 The adult vaccines segment is subdivided into preventive vaccines and therapeutic vaccines. On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA further country level analysis of regions is provided to determine the market size and forecast for each segment and sub-segment of the market across the globe. The major companies profiled in this report includes F. Hoffmann-La Roche AG, GlaxoSmithKline plc., AbbVie, Inc., Amgen, Inc., Merck & Co., Inc., Alligator Bioscience, UbiVac, Bristol-Myers Squibb, Novartis International AG, and AstraZeneca plc. Key Benefits
Send Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/3578 Like it? Share it!More by this author |